凯普生物
(300639)
| 流通市值：40.40亿 | | | 总市值：41.44亿 |
| 流通股本：6.30亿 | | | 总股本：6.47亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 300,069,541.11 | 125,833,690.97 | 669,642,058.53 | 485,871,698.54 |
| 营业总成本 | 298,801,280.04 | 151,542,295.24 | 774,736,219.2 | 576,383,507.2 |
| 其他经营收益 | | | | |
| 营业利润 | 45,518,703.65 | -3,450,237.58 | -156,405,635.02 | -170,834,411.01 |
| 利润总额 | 40,380,469.55 | -3,668,365.02 | -169,320,860.02 | -177,359,575.41 |
| 净利润 | 25,393,331.37 | -6,428,189.76 | -182,280,400.25 | -189,378,521.58 |
| 每股收益 | | | | |
| 其他综合收益 | 53,373,097.12 | 74,742,906.91 | -66,747,487.14 | -37,137,367.19 |
| 综合收益总额 | 78,766,428.49 | 68,314,717.15 | -249,027,887.39 | -226,515,888.77 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,697,209,459.09 | 1,787,822,042.89 | 1,894,105,046.69 | 1,976,063,479.06 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,501,634,682.81 | 2,435,590,251.47 | 2,253,561,354.61 | 2,306,342,384.79 |
| 资产总计 | 4,198,844,141.9 | 4,223,412,294.36 | 4,147,666,401.3 | 4,282,405,863.85 |
| 流动负债: | | | | |
| 流动负债合计 | 315,107,516.41 | 337,333,646.64 | 352,325,125.28 | 390,162,989.67 |
| 非流动负债: | | | | |
| 非流动负债合计 | 160,182,399.16 | 166,499,892.84 | 133,530,085.44 | 163,599,095.31 |
| 负债合计 | 475,289,915.57 | 503,833,539.48 | 485,855,210.72 | 553,762,084.98 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,808,009,322.68 | 3,806,153,315.19 | 3,748,354,128.79 | 3,840,830,191.05 |
| 股东权益合计 | 3,723,554,226.33 | 3,719,578,754.88 | 3,661,811,190.58 | 3,728,643,778.87 |
| 负债和股东权益合计 | 4,198,844,141.9 | 4,223,412,294.36 | 4,147,666,401.3 | 4,282,405,863.85 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 421,003,141.92 | 201,283,401.92 | 1,119,278,091.08 | 714,124,706.55 |
| 经营活动现金流出小计 | 350,289,628.99 | 176,332,576.47 | 777,669,344.27 | 592,914,306.34 |
| 经营活动产生的现金流量净额 | 70,713,512.93 | 24,950,825.45 | 341,608,746.81 | 121,210,400.21 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 828,383,789.71 | 251,979,925.52 | 789,224,892.25 | 660,493,420.58 |
| 投资活动现金流出小计 | 957,612,677.17 | 571,829,595.04 | 932,472,375.02 | 685,644,840.57 |
| 投资活动产生的现金流量净额 | -129,228,887.46 | -319,849,669.52 | -143,247,482.77 | -25,151,419.99 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | 59,812,675.91 | 54,000,000 |
| 筹资活动现金流出小计 | 23,981,872.38 | 12,271,278.88 | 202,928,217.85 | 130,776,317.32 |
| 筹资活动产生的现金流量净额 | -23,981,872.38 | -12,271,278.88 | -143,115,541.94 | -76,776,317.32 |
| 汇率变动对现金及现金等价物的影响 | -18,357,360.61 | -11,941,768.92 | -9,394,780.05 | 3,388,635.5 |
| 现金及现金等价物净增加额 | -100,854,607.52 | -319,111,891.87 | 45,850,942.05 | 22,671,298.4 |
| 期末现金及现金等价物余额 | 607,112,110.62 | 388,877,064.24 | 707,966,718.14 | 684,787,074.49 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -100,854,607.52 | - | 45,850,942.05 | - |